Skip to Content
Not all colorectal cancer treatments are the same. Find out more >

Ziv-aflibercept Pregnancy and Breastfeeding Warnings

Ziv-aflibercept is also known as: Zaltrap

Ziv-aflibercept Pregnancy Warnings

Ziv-aflibercept has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryo-fetal toxicity and teratogenicity. There are no controlled data in human pregnancy. The manufacturer recommends that females and males of reproductive potential should use highly effective contraception during and up to a minimum of 3 months after the last dose of treatment. If ziv-aflibercept is used during pregnancy, or if the patient becomes pregnant during treatment, the patient should be apprised of the potential hazard to the developing fetus. The manufacturer recommends that ziv-aflibercept only be used during pregnancy when the potential benefits outweigh the potential risks to the developing fetus.

See references

Ziv-aflibercept Breastfeeding Warnings

There are no data on the excretion of ziv-aflibercept into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ.

References for breastfeeding information

  1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.